ZA200109804B - Thiazole and oxazole derivatives and their pharmaceutical use. - Google Patents
Thiazole and oxazole derivatives and their pharmaceutical use. Download PDFInfo
- Publication number
- ZA200109804B ZA200109804B ZA200109804A ZA200109804A ZA200109804B ZA 200109804 B ZA200109804 B ZA 200109804B ZA 200109804 A ZA200109804 A ZA 200109804A ZA 200109804 A ZA200109804 A ZA 200109804A ZA 200109804 B ZA200109804 B ZA 200109804B
- Authority
- ZA
- South Africa
- Prior art keywords
- methyl
- phenyl
- agonist
- composition
- thiazol
- Prior art date
Links
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 title description 2
- 150000007978 oxazole derivatives Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 92
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 79
- 239000000556 agonist Substances 0.000 claims description 62
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 54
- 239000000203 mixture Substances 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 47
- 239000000126 substance Substances 0.000 claims description 32
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 claims description 28
- 101000741788 Homo sapiens Peroxisome proliferator-activated receptor alpha Proteins 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 20
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 19
- 230000003247 decreasing effect Effects 0.000 claims description 17
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- -1 {4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5- yl}methyl Chemical group 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 206010022489 Insulin Resistance Diseases 0.000 claims description 9
- 230000001404 mediated effect Effects 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 150000003626 triacylglycerols Chemical class 0.000 claims description 8
- 101100168093 Caenorhabditis elegans cogc-2 gene Proteins 0.000 claims description 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 7
- 101100221487 Mus musculus Cog2 gene Proteins 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 230000036772 blood pressure Effects 0.000 claims description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 3
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 3
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 3
- 208000022531 anorexia Diseases 0.000 claims description 3
- 206010061428 decreased appetite Diseases 0.000 claims description 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000000841 delta opiate receptor agonist Substances 0.000 claims 25
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 claims 1
- 239000000543 intermediate Substances 0.000 description 33
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000007787 solid Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 10
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 102000008946 Fibrinogen Human genes 0.000 description 8
- 108010049003 Fibrinogen Proteins 0.000 description 8
- 229940012952 fibrinogen Drugs 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 description 6
- 102000007330 LDL Lipoproteins Human genes 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 108010028924 PPAR alpha Proteins 0.000 description 5
- 102000023984 PPAR alpha Human genes 0.000 description 5
- 108010016731 PPAR gamma Proteins 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 4
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- GYQRIAVRKLRQKP-UHFFFAOYSA-N methyl 2-chloro-3-oxobutanoate Chemical compound COC(=O)C(Cl)C(C)=O GYQRIAVRKLRQKP-UHFFFAOYSA-N 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 229910010082 LiAlH Inorganic materials 0.000 description 3
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940123464 Thiazolidinedione Drugs 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 150000001350 alkyl halides Chemical class 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 3
- 230000000269 nucleophilic effect Effects 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 150000003536 tetrazoles Chemical group 0.000 description 3
- 150000001467 thiazolidinediones Chemical class 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 2
- WEJHBEDHLLBJFW-UHFFFAOYSA-N 4-(trifluoromethyl)benzamide Chemical compound NC(=O)C1=CC=C(C(F)(F)F)C=C1 WEJHBEDHLLBJFW-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 108010015181 PPAR delta Proteins 0.000 description 2
- 101150014691 PPARA gene Proteins 0.000 description 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 229940125753 fibrate Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000008570 general process Effects 0.000 description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 2
- 201000008980 hyperinsulinism Diseases 0.000 description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 238000011809 primate model Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- MRQBQZNVLNJRQR-UXBLZVDNSA-N (e)-3-[2-methyl-4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methoxy]phenyl]prop-2-enoic acid Chemical compound CC=1N=C(C=2C=CC(=CC=2)C(F)(F)F)SC=1COC1=CC=C(\C=C\C(O)=O)C(C)=C1 MRQBQZNVLNJRQR-UXBLZVDNSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- KYABLFQOPKKJCJ-UHFFFAOYSA-N 2-[2-methyl-4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-5-yl]methoxy]phenoxy]acetic acid Chemical compound CC=1N=C(C=2C=CC(=CC=2)C(F)(F)F)OC=1COC1=CC=C(OCC(O)=O)C(C)=C1 KYABLFQOPKKJCJ-UHFFFAOYSA-N 0.000 description 1
- IPRFNMJROWWFBH-UHFFFAOYSA-N 4-(trifluoromethyl)benzenecarbothioamide Chemical compound NC(=S)C1=CC=C(C(F)(F)F)C=C1 IPRFNMJROWWFBH-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- PGRLMMNBSYFFPP-UHFFFAOYSA-N 4-methyl-5-[[4-(2h-tetrazol-5-ylmethoxy)phenoxy]methyl]-2-[4-(trifluoromethyl)phenyl]-1,3-oxazole Chemical compound CC=1N=C(C=2C=CC(=CC=2)C(F)(F)F)OC=1COC(C=C1)=CC=C1OCC=1N=NNN=1 PGRLMMNBSYFFPP-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 229940123073 Angiotensin antagonist Drugs 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- YDBLKRPLXZNVNB-UHFFFAOYSA-N GW 501516 Chemical compound CC=1N=C(C=2C=CC(=CC=2)C(F)(F)F)SC=1CSC1=CC=C(OCC(O)=O)C(C)=C1 YDBLKRPLXZNVNB-UHFFFAOYSA-N 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 1
- 101000741797 Homo sapiens Peroxisome proliferator-activated receptor delta Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 229940124754 PPAR-alpha/gamma agonist Drugs 0.000 description 1
- 101710117029 Peroxisome proliferator-activated receptor delta Proteins 0.000 description 1
- 229940122054 Peroxisome proliferator-activated receptor delta agonist Drugs 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000002293 adipogenic effect Effects 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 239000002369 angiotensin antagonist Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- JMBHNRDFFCWPHT-UHFFFAOYSA-N ethyl 3-bromo-4-oxopentanoate Chemical compound CCOC(=O)CC(Br)C(C)=O JMBHNRDFFCWPHT-UHFFFAOYSA-N 0.000 description 1
- LPIXRQSYBTUXOQ-UHFFFAOYSA-N ethyl 4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-5-carboxylate Chemical compound CC1=C(C(=O)OCC)SC(C=2C=CC(=CC=2)C(F)(F)F)=N1 LPIXRQSYBTUXOQ-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 description 1
- 229960004340 lacidipine Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000004322 lipid homeostasis Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- SEXBJUCRCRFSIZ-UHFFFAOYSA-N methyl 3-[4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methoxy]phenyl]propanoate Chemical compound C1=CC(CCC(=O)OC)=CC=C1OCC1=C(C)N=C(C=2C=CC(=CC=2)C(F)(F)F)S1 SEXBJUCRCRFSIZ-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003893 regulation of appetite Effects 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 108091008012 small dense LDL Proteins 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/26—Radicals substituted by sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9914977.5A GB9914977D0 (en) | 1999-06-25 | 1999-06-25 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200109804B true ZA200109804B (en) | 2003-02-28 |
Family
ID=10856125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200109804A ZA200109804B (en) | 1999-06-25 | 2001-11-28 | Thiazole and oxazole derivatives and their pharmaceutical use. |
Country Status (29)
Country | Link |
---|---|
US (2) | US6710063B1 (es) |
EP (1) | EP1189895B8 (es) |
JP (2) | JP3490704B2 (es) |
KR (1) | KR100668026B1 (es) |
CN (1) | CN1164579C (es) |
AR (1) | AR035320A1 (es) |
AT (1) | ATE297384T1 (es) |
AU (1) | AU765347B2 (es) |
BR (1) | BR0011891A (es) |
CA (1) | CA2377126C (es) |
CO (1) | CO5180622A1 (es) |
CZ (1) | CZ300654B6 (es) |
DE (1) | DE60020701T2 (es) |
ES (1) | ES2243276T3 (es) |
GB (1) | GB9914977D0 (es) |
HK (1) | HK1042897B (es) |
HU (1) | HUP0201858A3 (es) |
IL (2) | IL146634A0 (es) |
MX (1) | MXPA01013244A (es) |
MY (1) | MY120090A (es) |
NO (1) | NO321872B1 (es) |
NZ (1) | NZ515676A (es) |
PE (1) | PE20010406A1 (es) |
PL (1) | PL353135A1 (es) |
PT (1) | PT1189895E (es) |
TR (1) | TR200103612T2 (es) |
TW (1) | TWI256389B (es) |
WO (1) | WO2001000603A1 (es) |
ZA (1) | ZA200109804B (es) |
Families Citing this family (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0024362D0 (en) * | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
GB0024361D0 (en) * | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
UA82048C2 (uk) | 2000-11-10 | 2008-03-11 | Эли Лилли Энд Компани | Агоністи альфа-рецепторів, активованих проліфератором пероксисом |
GB0031107D0 (en) * | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
US7105551B2 (en) | 2000-12-20 | 2006-09-12 | Smithkline Beecham Corporation | Thiazole derivatives for treating PPAR related disorders |
GB0031103D0 (en) * | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
JP2004517100A (ja) * | 2000-12-20 | 2004-06-10 | グラクソ グループ リミテッド | hPPARアルファアゴニストとしての置換オキサゾールおよびチアゾール |
GB0031109D0 (en) * | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
US20040072838A1 (en) | 2000-12-20 | 2004-04-15 | Pierette Banker | Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors |
EP1911462A3 (en) | 2001-01-26 | 2011-11-30 | Schering Corporation | Compositions comprising a sterol absorption inhibitor |
AU2002243778A1 (en) * | 2001-02-02 | 2002-09-19 | Smithkline Beecham Corporation | Treatment of ppar mediated diseases |
EP1371650A4 (en) * | 2001-03-23 | 2005-05-04 | Nippon Chemiphar Co | ACTIVATED RECEPTOR ACTIVATOR BY PEROXYSOME PROLIFIERS |
WO2002083131A1 (en) * | 2001-04-13 | 2002-10-24 | The Regents Of The University Of California | Activators and ligands of ppar-beta/delta for the treatment of skin conditions |
AU2002342244B2 (en) * | 2001-05-15 | 2005-06-16 | F. Hoffmann-La Roche Ag | Carboxylic acid substituted oxazole derivatives for use as PPAR-alpha and -gamma activators in the treatment of diabetes |
GB0113231D0 (en) * | 2001-05-31 | 2001-07-25 | Glaxo Group Ltd | Chemical compounds |
KR101021817B1 (ko) | 2001-07-17 | 2011-03-17 | 데이진 가부시키가이샤 | PPAR δ활성화 작용을 측정하는 것을 특징으로 하는 물질의 선택방법 및 약제 |
US6869967B2 (en) | 2001-07-30 | 2005-03-22 | Novo Nordisk A/S | Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives |
US7067530B2 (en) | 2001-07-30 | 2006-06-27 | Novo Nordisk A/S | Compounds, their preparation and use |
CN1330641C (zh) * | 2001-08-10 | 2007-08-08 | 日本化学医药株式会社 | 过氧化物酶体增殖剂响应受体δ活化剂 |
EP1435946B8 (en) * | 2001-09-14 | 2013-12-18 | Amgen Inc. | Linked biaryl compounds |
US7220877B2 (en) | 2001-10-17 | 2007-05-22 | Novo Nordisk A/S | Compounds, their preparation and use |
ES2290439T3 (es) * | 2002-02-25 | 2008-02-16 | Eli Lilly And Company | Moduladores del receptor activado del proliferador de peroxisomas. |
EP1480642B1 (en) | 2002-02-25 | 2008-11-26 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
WO2003074504A2 (en) * | 2002-02-28 | 2003-09-12 | Smithkline Beecham Corporation | Process and intermediates for preparing phenylthiomethyl-thiazoles or oxazoles |
US7319104B2 (en) | 2002-03-01 | 2008-01-15 | Smithkline Beecham Corporation | hPPARs activators |
US6833380B2 (en) | 2002-03-07 | 2004-12-21 | Warner-Lambert Company, Llc | Compounds that modulate PPAR activity and methods of preparation |
US6867224B2 (en) | 2002-03-07 | 2005-03-15 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods of preparation |
US20030207924A1 (en) * | 2002-03-07 | 2003-11-06 | Xue-Min Cheng | Compounds that modulate PPAR activity and methods of preparation |
US6716842B2 (en) * | 2002-04-05 | 2004-04-06 | Warner-Lambert Company, Llc | Antidiabetic agents |
US6875780B2 (en) | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
KR100474202B1 (ko) * | 2002-05-04 | 2005-03-08 | 강헌중 | 티아졸 유도체의 제조방법 및 이를 제조하기 위한 중간체 |
JP2004277397A (ja) * | 2002-05-24 | 2004-10-07 | Takeda Chem Ind Ltd | 1,2−アゾール誘導体 |
EP1513817A1 (en) * | 2002-05-24 | 2005-03-16 | Takeda Pharmaceutical Company Limited | 1, 2-azole derivatives with hypoglycemic and hypolipidemic activity |
AU2003249879B2 (en) * | 2002-07-03 | 2008-12-18 | F. Hoffmann-La Roche Ag | Oxazole derivatives and their use as insulin sensitizers |
CN1665500A (zh) * | 2002-07-09 | 2005-09-07 | 百时美施贵宝公司 | 用作抗糖尿病和抗肥胖症试剂的取代杂环衍生物及方法 |
PT1537091E (pt) * | 2002-08-30 | 2010-11-11 | Hoffmann La Roche | Novos compostos de 2-ariltiazole como agonistas de ppar-alfa e de ppar-gama |
US7091245B2 (en) | 2002-09-05 | 2006-08-15 | Novo Novdisk A/S | Compounds, their preparation and use |
JP2004123732A (ja) * | 2002-09-10 | 2004-04-22 | Takeda Chem Ind Ltd | 5員複素環化合物 |
AU2003262023A1 (en) | 2002-09-10 | 2004-04-30 | Takeda Pharmaceutical Company Limited | Five-membered heterocyclic compounds |
BR0314261A (pt) | 2002-09-12 | 2005-07-26 | Hoffmann La Roche | Compostos, processo de preparação de um composto, composição farmacêutica que compreende o mesmo, utilização de um composto, método para tratamento e/ou profilaxia de enfermidades e utilização e/ou método de tratamento |
US7162262B2 (en) | 2002-09-23 | 2007-01-09 | Telefonaktiebolaget Lm Ericsson (Publ) | Methods, systems and computer program products for requesting received power levels based on received block error rates utilizing an anti-windup and/or emergency procedure |
US7129268B2 (en) | 2002-10-28 | 2006-10-31 | Novo Nordisk A/S | Peroxisome proliferator activated receptor-active arylene acetic acid derivatives |
MXPA05004402A (es) | 2002-10-28 | 2005-07-26 | Novo Nordisk As | Compuestos novedosos y su uso como moduladores de receptores activados por proliferador de peroxisoma. |
US20050080115A1 (en) | 2002-10-28 | 2005-04-14 | Lone Jeppesen | Novel compounds, their preparation and use |
BR0315667A (pt) | 2002-10-28 | 2005-09-06 | Novo Nordisk As | Composto, uso de um composto, composição farmacêutica, e, método para o tratamento |
EP2385032A1 (en) * | 2002-11-08 | 2011-11-09 | Takeda Pharmaceutical Company Limited | GPR40 Receptor function regulator |
RU2315767C2 (ru) | 2002-11-25 | 2008-01-27 | Ф.Хоффманн-Ля Рош Аг | Индолилпроизводные, способ их получения, фармацевтическая композиция, способ лечения и/или профилактики заболеваний |
US7816385B2 (en) | 2002-12-20 | 2010-10-19 | High Point Pharmaceuticals, Llc | Dimeric dicarboxylic acid derivatives, their preparation and use |
WO2004063155A1 (en) * | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Fused heterocyclic derivatives as ppar modulators |
US7148246B2 (en) * | 2003-02-27 | 2006-12-12 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals |
DE10308354A1 (de) * | 2003-02-27 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Cycloalkylderivate mit biosteren Carbonsäure-Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US7244763B2 (en) | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
US6987118B2 (en) | 2003-05-21 | 2006-01-17 | Pfizer Inc. | Tetrahydroisoquinoline derivatives as PPAR-alpha activators |
WO2005042478A2 (en) | 2003-09-19 | 2005-05-12 | Janssen Pharmaceutica, N.V. | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
DK1670744T5 (da) | 2003-09-19 | 2012-11-26 | Janssen Pharmaceutica Nv | 4-((Phenoxyalkyl)-thio)-phenoxyeddikesyrer og analoge |
RU2349587C2 (ru) | 2003-09-22 | 2009-03-20 | Оно Фармасьютикал Ко., Лтд. | Производное фенилуксусной кислоты и его применение |
CA2547430A1 (en) | 2003-11-26 | 2005-06-09 | Takeda Pharmaceutical Company Limited | Receptor function regulating agent |
WO2005060958A1 (en) * | 2003-12-19 | 2005-07-07 | Kalypsys, Inc. | (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes |
EP1697339A1 (en) | 2003-12-25 | 2006-09-06 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl)propanoic acid derivatives |
WO2005063725A1 (ja) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | フェニルプロパン酸誘導体 |
EP1737809B1 (en) * | 2004-02-27 | 2013-09-18 | Amgen, Inc | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
WO2005097762A2 (en) | 2004-04-01 | 2005-10-20 | Aventis Pharmaceuticals Inc. | 1,3,4-oxadiazol-2-ones as ppar delta modulators |
CA2561230A1 (en) | 2004-04-01 | 2005-10-20 | Aventis Pharmaceuticals Inc. | 1,3,4-oxadiazol-2-ones as ppar delta modulators and their use thereof |
JP2007530703A (ja) * | 2004-04-01 | 2007-11-01 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | Msおよびその他の脱髄疾患を治療するためのペルオキシソーム増殖因子活性化受容体デルタアゴニストの使用 |
DE602004004631D1 (de) | 2004-04-01 | 2007-03-22 | Sanofi Aventis Deutschland | Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika |
EP1745003B1 (en) | 2004-05-05 | 2010-10-27 | High Point Pharmaceuticals, LLC | Novel compounds, their preparation and use |
EP1745014B1 (en) | 2004-05-05 | 2011-07-06 | High Point Pharmaceuticals, LLC | Novel compounds, their preparation and use |
PE20060315A1 (es) * | 2004-05-24 | 2006-05-15 | Irm Llc | Compuestos de tiazol como moduladores de ppar |
JP2008500358A (ja) * | 2004-05-25 | 2008-01-10 | メタボレックス インコーポレーティッド | Pparのモジュレーターとしての、二環式の置換されたトリアゾール、およびこれらの調製方法 |
CA2567437A1 (en) * | 2004-05-25 | 2005-12-08 | Metabolex, Inc. | Substituted triazoles as modulators of ppar and methods of their preparation |
JP2007269630A (ja) * | 2004-06-23 | 2007-10-18 | Toudai Tlo Ltd | インスリン分泌促進剤 |
MY147518A (en) | 2004-09-15 | 2012-12-31 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
JP2008517902A (ja) * | 2004-10-22 | 2008-05-29 | ホンジュン カン | アルキルアリルサルファイド誘導体の製造方法及び新規なサルファイド化合物 |
ES2328384T3 (es) * | 2004-11-23 | 2009-11-12 | Warner-Lambert Company Llc | Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia. |
EP1829863A4 (en) * | 2004-11-26 | 2009-04-22 | Takeda Pharmaceutical | ARYLALCANOIC ACID DERIVATIVE |
CA2598821C (en) * | 2004-12-31 | 2011-05-31 | Heonjoong Kang | Organoselenium containing compounds and their use |
ES2379800T3 (es) * | 2004-12-31 | 2012-05-03 | Seoul National University Industry Foundation | Compuestos con contenido en organoselenio su uso |
FR2880886B1 (fr) * | 2005-01-14 | 2007-04-06 | Merck Sante Soc Par Actions Si | Derives de l'acide 6-phenylhex-5-enoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique |
US20090054493A1 (en) * | 2005-02-25 | 2009-02-26 | Heonjoong Kang Kang | Thiazole derivatives as ppar delta ligands and their manufacturing process |
WO2006121223A1 (en) * | 2005-05-07 | 2006-11-16 | Heon Joong Kang | Process for preparing ligands of ppardelta and the intermediate compounds for preparing the same |
US7465804B2 (en) * | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
EP1889613A4 (en) * | 2005-05-27 | 2010-11-24 | Shionogi & Co | PHARMACEUTICAL COMPOSITION COMPRISING VITAMIN K |
WO2006126514A1 (ja) | 2005-05-27 | 2006-11-30 | Shionogi & Co., Ltd. | イソキサゾール骨格を有するアリール酢酸誘導体 |
MX2007016374A (es) | 2005-06-30 | 2008-03-05 | Novo Nordisk As | Acidos fenoxiaceticos como activadores ppar delta. |
CA2621949A1 (en) | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
JO3006B1 (ar) | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
CA2624102A1 (en) * | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
KR20080048520A (ko) * | 2005-09-29 | 2008-06-02 | 사노피-아벤티스 | 페닐 그룹을 갖는, 페닐- 및 피리딜-1,2,4-옥사디아졸론유도체, 이의 제조 방법 및 약제로서의 이의 용도 |
CN103224477A (zh) | 2005-12-22 | 2013-07-31 | 高点制药有限责任公司 | 作为PPAR-δ活化剂的苯氧基乙酸 |
CN101400663A (zh) * | 2006-01-10 | 2009-04-01 | 史密丝克莱恩比彻姆公司 | {2-甲基-4-[4-甲基-2-(4-三氟甲基苯基)噻唑-5-基甲硫基]苯氧基}-乙酸的多晶型 |
CN101007790B (zh) * | 2006-01-27 | 2011-03-30 | 北京摩力克科技有限公司 | 草氨酸衍生物、其制备方法和医药用途 |
CN101374834B (zh) * | 2006-02-03 | 2011-12-14 | 伊莱利利公司 | 用于调节fxr的化合物和方法 |
JP2009132620A (ja) * | 2006-03-07 | 2009-06-18 | Astellas Pharma Inc | フェニルチアゾール誘導体 |
EP1999098A2 (en) | 2006-03-09 | 2008-12-10 | High Point Pharmaceuticals, LLC | Compounds that modulate ppar activity, their preparation and use |
MX2008011615A (es) * | 2006-03-14 | 2008-09-22 | Amgen Inc | Derivados de acidos carboxilicos biciclicos utiles para tratar trastornos metabolicos. |
BRPI0710266B8 (pt) * | 2006-04-18 | 2021-05-25 | Nippon Chemiphar Co | composto, medicamento, e, uso de um composto |
PE20080188A1 (es) | 2006-04-18 | 2008-03-10 | Janssen Pharmaceutica Nv | Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol |
WO2007141295A1 (en) * | 2006-06-08 | 2007-12-13 | High Point Pharmaceuticals, Llc | Process for preparing phenoxy acetic acid derivatives |
US20080004281A1 (en) * | 2006-06-28 | 2008-01-03 | Kalypsys, Inc. | Methods for the modulation of crp by the selective modulation of ppar delta |
WO2008016175A1 (fr) * | 2006-08-03 | 2008-02-07 | Nippon Chemiphar Co., Ltd. | Agent activant de récepteur activé par les proliférateurs des peroxysomes |
CA2662242C (en) * | 2006-09-07 | 2012-06-12 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
AU2007293028B2 (en) | 2006-09-07 | 2012-05-31 | Amgen Inc. | Heterocyclic GPR40 modulators |
US9308198B2 (en) | 2006-09-08 | 2016-04-12 | Rhode Island Hospital | Treatment, prevention, and reversal of alcohol-induced brain disease |
KR101922515B1 (ko) * | 2006-09-08 | 2019-02-20 | 로드아일랜드하스피틀 | 알코올 유발성 간 질환의 치료, 예방 및 역행 |
RU2444514C2 (ru) | 2006-12-02 | 2012-03-10 | Сеул Нэшнл Юниверсити Индастри Фаундейшн | Арильные соединения в качестве лигандов ppar и их применение |
US20080187928A1 (en) | 2006-12-29 | 2008-08-07 | The Salk Institute For Biological Studies | Methods for enhancing exercise performance |
US8236831B2 (en) | 2007-01-08 | 2012-08-07 | Seoul National University Industry Foundation | Thiazole compound (as PPARδ) ligand and pharmaceutical, cosmetic and health food comprised thereof |
CA2677706A1 (en) * | 2007-02-22 | 2008-08-28 | Irm Llc | Compounds and methods for modulating g protein-coupled receptors |
JP2010524932A (ja) * | 2007-04-16 | 2010-07-22 | アムジエン・インコーポレーテツド | 置換ビフェニルフェノキシ−、チオフェニル−及びアミノフェニルプロパン酸gpr40調節物質 |
WO2008154023A1 (en) * | 2007-06-11 | 2008-12-18 | Cerenis Therapeutics S.A. | Novel uses of ppar delta agonists |
GB0712653D0 (en) | 2007-06-28 | 2007-08-08 | Syngenta Ltd | Novel herbicides |
GB0717082D0 (en) | 2007-09-03 | 2007-10-10 | Syngenta Ltd | Novel herbicides |
MX2010003876A (es) | 2007-10-10 | 2010-12-02 | Amgen Inc | Moduladores de gpr40 bifenilo- sustituidos. |
WO2009078981A2 (en) * | 2007-12-13 | 2009-06-25 | Sri International | Ppar-delta ligands and methods of their use |
EP2260017A1 (en) | 2008-03-06 | 2010-12-15 | Amgen, Inc | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
JP5474769B2 (ja) | 2008-04-15 | 2014-04-16 | 日本ケミファ株式会社 | ペルオキシソーム増殖剤活性化受容体の活性化剤 |
CN101643451B (zh) | 2008-08-07 | 2013-03-06 | 浙江海正药业股份有限公司 | 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法 |
US8748462B2 (en) | 2008-10-15 | 2014-06-10 | Amgen Inc. | Spirocyclic GPR40 modulators |
EP2346498B1 (en) | 2008-10-17 | 2018-12-26 | Cymabay Therapeutics, Inc. | Methods of reducing small, dense ldl particles |
US20120316346A1 (en) * | 2010-02-25 | 2012-12-13 | Snu R & Db Foundation | Selenalzole derivative having ligand which activates peroxisome proliferator activated receptor (ppar), preparing method thereof and usage of the chemical compounds |
CN102285933B (zh) | 2010-06-18 | 2016-03-09 | 浙江海正药业股份有限公司 | 一种对亚型过氧化物酶增殖物激活受体具有激动作用的化合物、其制备方法和应用 |
WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
JP2013538215A (ja) * | 2010-08-31 | 2013-10-10 | エスエヌユー アールアンドディービー ファウンデーション | PPARδアゴニストの胎児再プログラミング用途 |
US9695137B2 (en) * | 2013-03-14 | 2017-07-04 | The University Of Toledo | Analogs of peroxisome proliferator activated receptor (PPAR) agonists, and methods of using the same |
US10181018B2 (en) * | 2013-03-14 | 2019-01-15 | The University Of Toledo | Analogs of proxisome proliferator activated receptor (PPAR) agonists and methods of using the same |
ES2811087T3 (es) | 2013-09-09 | 2021-03-10 | Vtv Therapeutics Llc | Uso de agonistas de PPAR-delta para tratar la atrofia muscular |
JP7397491B2 (ja) | 2018-10-23 | 2023-12-13 | 国立研究開発法人科学技術振興機構 | PPARδ活性化剤 |
US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
WO2022189856A1 (en) * | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS644688A (en) * | 1987-06-26 | 1989-01-09 | Tokuyama Soda Kk | Photochromic composition |
JPH0793082B2 (ja) * | 1987-09-07 | 1995-10-09 | 株式会社明電舎 | 真空インタラプタの化成方法 |
JP2551151B2 (ja) * | 1989-06-22 | 1996-11-06 | 神鋼電機株式会社 | 潜熱回収方式の給湯装置における放熱装置 |
JP3039009B2 (ja) * | 1991-06-25 | 2000-05-08 | ソニー株式会社 | 固体撮像素子の駆動装置 |
TW268952B (es) | 1993-02-26 | 1996-01-21 | Takeda Pharm Industry Co Ltd | |
US5591862A (en) * | 1993-06-11 | 1997-01-07 | Takeda Chemical Industries, Ltd. | Tetrazole derivatives, their production and use |
JP3466273B2 (ja) | 1993-06-11 | 2003-11-10 | 武田薬品工業株式会社 | テトラゾール誘導体、その製造法およびそれを含んでなる医薬 |
JP3836521B2 (ja) | 1994-08-10 | 2006-10-25 | 武田薬品工業株式会社 | 2,4−チアゾリジンジオン誘導体、その製造法およびそれを含んでなる医薬組成物 |
JP2850809B2 (ja) | 1994-11-02 | 1999-01-27 | 武田薬品工業株式会社 | 2,4−オキサゾリジンジオン誘導体およびそれを含んでなる医薬組成物 |
JP3880108B2 (ja) | 1994-11-02 | 2007-02-14 | 武田薬品工業株式会社 | 2,4−オキサゾリジンジオン誘導体、その製造法およびそれを含んでなる医薬組成物 |
JPH08325250A (ja) * | 1995-05-31 | 1996-12-10 | Sumitomo Metal Ind Ltd | 新規置換フェノール誘導体 |
JPH08325263A (ja) * | 1995-05-31 | 1996-12-10 | Sumitomo Metal Ind Ltd | 新規2−アミノ−3−フェニルプロピオン酸誘導体 |
WO1997028149A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
US5847008A (en) * | 1996-02-02 | 1998-12-08 | Merck & Co., Inc. | Method of treating diabetes and related disease states |
US5859051A (en) * | 1996-02-02 | 1999-01-12 | Merck & Co., Inc. | Antidiabetic agents |
GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
JP3215048B2 (ja) | 1996-04-03 | 2001-10-02 | 日本たばこ産業株式会社 | プロピオン酸誘導体及びその用途 |
KR20000068151A (ko) * | 1996-08-19 | 2000-11-25 | 미즈노 마사루 | 프로피온산 유도체 및 그의 용도 |
CA2295930C (en) | 1997-07-24 | 2010-12-14 | Yamanouchi Pharmaceutical Co., Ltd. | Pharmaceutical compositions having cholesterol-lowering effect |
EP1067109B1 (en) * | 1998-03-10 | 2009-12-09 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
KR102220553B1 (ko) * | 2015-03-10 | 2021-02-26 | 한국전자통신연구원 | 표시 패널 및 그것을 포함하는 표시 장치 |
-
1999
- 1999-06-25 GB GBGB9914977.5A patent/GB9914977D0/en not_active Ceased
-
2000
- 2000-06-22 PT PT00943847T patent/PT1189895E/pt unknown
- 2000-06-22 TR TR2001/03612T patent/TR200103612T2/xx unknown
- 2000-06-22 AU AU58171/00A patent/AU765347B2/en not_active Ceased
- 2000-06-22 EP EP00943847A patent/EP1189895B8/en not_active Expired - Lifetime
- 2000-06-22 KR KR1020017016616A patent/KR100668026B1/ko not_active IP Right Cessation
- 2000-06-22 DE DE60020701T patent/DE60020701T2/de not_active Expired - Lifetime
- 2000-06-22 PL PL00353135A patent/PL353135A1/xx not_active Application Discontinuation
- 2000-06-22 ES ES00943847T patent/ES2243276T3/es not_active Expired - Lifetime
- 2000-06-22 CN CNB008094969A patent/CN1164579C/zh not_active Expired - Fee Related
- 2000-06-22 MX MXPA01013244A patent/MXPA01013244A/es active IP Right Grant
- 2000-06-22 HU HU0201858A patent/HUP0201858A3/hu unknown
- 2000-06-22 BR BR0011891-5A patent/BR0011891A/pt active Search and Examination
- 2000-06-22 IL IL14663400A patent/IL146634A0/xx active IP Right Grant
- 2000-06-22 JP JP2001507012A patent/JP3490704B2/ja not_active Expired - Fee Related
- 2000-06-22 WO PCT/EP2000/005720 patent/WO2001000603A1/en active IP Right Grant
- 2000-06-22 US US10/018,935 patent/US6710063B1/en not_active Expired - Fee Related
- 2000-06-22 AT AT00943847T patent/ATE297384T1/de not_active IP Right Cessation
- 2000-06-22 NZ NZ515676A patent/NZ515676A/en not_active IP Right Cessation
- 2000-06-22 CA CA002377126A patent/CA2377126C/en not_active Expired - Fee Related
- 2000-06-22 CZ CZ20014664A patent/CZ300654B6/cs not_active IP Right Cessation
- 2000-06-23 AR ARP000103161A patent/AR035320A1/es active IP Right Grant
- 2000-06-23 PE PE2000000630A patent/PE20010406A1/es not_active Application Discontinuation
- 2000-06-23 CO CO00047291A patent/CO5180622A1/es not_active Application Discontinuation
- 2000-06-23 MY MYPI20002859A patent/MY120090A/en unknown
- 2000-06-28 TW TW089112727A patent/TWI256389B/zh not_active IP Right Cessation
-
2001
- 2001-11-20 IL IL146634A patent/IL146634A/en not_active IP Right Cessation
- 2001-11-28 ZA ZA200109804A patent/ZA200109804B/en unknown
- 2001-12-13 NO NO20016078A patent/NO321872B1/no not_active IP Right Cessation
-
2002
- 2002-06-11 HK HK02104378.2A patent/HK1042897B/zh not_active IP Right Cessation
-
2003
- 2003-03-06 US US10/383,011 patent/US6723740B2/en not_active Expired - Fee Related
- 2003-04-01 JP JP2003098492A patent/JP2003313141A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200109804B (en) | Thiazole and oxazole derivatives and their pharmaceutical use. | |
JP4209681B2 (ja) | Ppar関連障害治療用のチアゾール誘導体 | |
KR100706735B1 (ko) | hPPAR 알파 활성제로서 치환된 옥사졸 및 티아졸유도체 | |
KR20040007633A (ko) | 심혈관 질환 및 이와 관련된 질환의 치료에 유용한 티아졸또는 옥사졸 유도체 | |
CZ2001490A3 (cs) | Oxazolové a thiazolové deriváty | |
US20040147571A1 (en) | Substituted oxazoles and thiazoles as hppar alpha agonists | |
EP1513796A2 (en) | Phenyloxyalkanoic acid derivatives as hppar activators | |
US7157479B2 (en) | Oxazol/thiazol-derivatives activators of the hPPAR-alpha receptor | |
US7439259B2 (en) | Thiazole derivatives for treating PPAR related disorders | |
US7141591B2 (en) | 1,2,4-oxadiazole derivatives as hPPAR alpha agonists | |
AU2002220902A1 (en) | 1, 2, 4-oxadiazole derivatives as hPPAR alpha agonists | |
JP2007508270A (ja) | I.a.ジスリピデミアの治療におけるhppar作用物質として使用するためのチアゾール−2−カルボキシアミド誘導体 |